• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Crude Oil Down Over 1%; Henry Schein Earnings Top Views

    8/7/23 12:01:28 PM ET
    $HSIC
    $SAGE
    $SQNS
    $TIVC
    Medical Specialities
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $HSIC alert in real time by email

    U.S. stocks were higher midway through trading, with the Dow Jones gaining more than 300 points on Monday.

    The Dow traded up 0.88% to 35,374.41 while the NASDAQ rose 0.12% to 13,925.71. The S&P 500, also rose, gaining, 0.56% to 4,502.9.

    Check This Out: Merck, Delta Air Lines And 2 Other Stocks Insiders Are Selling

     

    Leading and Lagging Sectors

    • Financials shares jumped by 1.2% on Monday.
    • In trading on Monday, information technology shares rose by just 0.1%.

     

    Top Headline

    Henry Schein Inc (NASDAQ:HSIC) reported better-than-expected second-quarter earnings.

    Henry Schein posted quarterly sales of $3.10 billion, slightly missing the consensus of $3.11 billion, up 2.3% Y/Y, including 0.2% decrease in local currencies excluding acquisitions, 2.9% growth from acquisitions, and a 0.4% decrease related to foreign currency exchange. Adjusted EPS of $1.31, up 0.8%, beat the estimate of $1.25.

     

    Equities Trading UP

    • Vistagen Therapeutics, Inc. (NASDAQ:VTGN) shares shot up 624% to $12.17 after the company announced its Phase 3 PALISADE-2 trial evaluating the efficacy, safety, and tolerability of fasedienol met the primary and secondary endpoints.
    • Shares of Tabula Rasa HealthCare, Inc. (NASDAQ:TRHC) got a boost, shooting 32% to $10.30 after the company reported better-than-expected second-quarter financial results.
    • Sequans Communications S.A. (NYSE:SQNS) shares were also up, gaining 31% to $2.80 after Renesas Electronics announced it will acquire the company. Sequans Communications also reported second-quarter results.

     

    Equities Trading DOWN

    • Sage Therapeutics, Inc. (NASDAQ:SAGE) shares dropped 49% to $18.45 after the company announced the FDA issued a Complete Response Letter for the New Drug Application for zuranolone in the treatment of adults with major depressive disorder.
    • Shares of Tivic Health Systems, Inc. (NASDAQ:TIVC) were down 37% to $0.0454 after the company priced $1.4 million public offering of 33.17 million shares at $0.041 per share.
    • Yellow Corporation (NASDAQ:YELL) was down, falling 37% to $2.25 after the company filed for bankruptcy under Chapter 11 of the U.S. Bankruptcy Code and is closing the business.

    Also Check This Out: Top 5 Industrials Stocks That May Explode This Month

     

    Commodities

    In commodity news, oil traded down 1.4% to $81.64 while gold traded down 0.3% at $1,971.20.

    Silver traded down 1.5% to $23.34 on Monday while copper fell 0.7% to $3.8395.

     

    Euro zone

    European shares were lower today. The eurozone’s STOXX 600 fell 0.04%, London’s FTSE 100 fell 0.22% while Spain’s IBEX 35 Index fell 0.32% The German DAX declined 0.11% French CAC 40 slipped 0.02% and Italy’s FTSE MIB Index declined 0.24%.

    The Halifax house price index in the UK declined by 2.4% year-over-year in July following a 2.6% fall in June. Industrial production in Germany fell by 1.5% month-over-month in June.

     

    Asia Pacific Markets

    Asian markets closed mixed on Monday, with Japan’s Nikkei 225 rising 0.19%, China’s Shanghai Composite Index falling 0.59% and Hong Kong’s Hang Seng Index declining 0.01%. India’s S&P BSE Sensex, meanwhile, rose 0.3%.

    China's foreign exchange reserves increased to $3.204 trillion at the end of July compared to $3.193 trillion in the previous month. Foreign exchange reserves in Singapore rose to SGD 452.5 billion in July from SGD 448.25 billion a month ago, while foreign exchange reserves in Hong Kong climbed to $421.6 billion in July.

    The index of leading economic indicators in Japan fell to 108.9 in June versus a revised reading of 109.1 in the prior month, while index of coincident economic indicators increased to 115.2 in June versus a final 114.3. Reserve assets in Japan rose to $1.254 trillion in July versus $1.247 trillion in the prior month.

     

    Economics

    Data on consumer credit will be released at 3:00 p.m. ET.

    Now Read This: This Analyst With 83% Accuracy Rate Sees Around 25% Upside In Amazon.com - Here Are 5 Stock Picks For Last Week From Wall Street's Most Accurate Analysts

     

    COVID-19 Update

    The U.S. has the highest number of coronavirus cases and deaths in the world, reporting a total of 107,564,390 cases with around 1,170,780 deaths. India confirmed a total of at least 44,995,980 cases and 531,910 deaths, while France reported over 40,138,560 COVID-19 cases with 167,640 deaths. In total, there were at least 692,636,680 cases of COVID-19 worldwide with more than 6,905,360 deaths.

    Get the next $HSIC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HSIC
    $SAGE
    $SQNS
    $TIVC

    CompanyDatePrice TargetRatingAnalyst
    Vistagen Therapeutics Inc.
    $VTGN
    12/17/2025$0.90Buy → Hold
    Jefferies
    Vistagen Therapeutics Inc.
    $VTGN
    12/17/2025Buy → Hold
    Maxim Group
    Vistagen Therapeutics Inc.
    $VTGN
    12/17/2025Outperform → Mkt Perform
    William Blair
    Vistagen Therapeutics Inc.
    $VTGN
    12/17/2025$1.00Buy → Hold
    Stifel
    Sequans Communications S.A.
    $SQNS
    12/10/2025$18.00Buy
    Lake Street
    Henry Schein Inc.
    $HSIC
    12/9/2025$86.00Overweight
    Barclays
    Sequans Communications S.A.
    $SQNS
    10/16/2025$13.00Buy
    B. Riley Securities
    Henry Schein Inc.
    $HSIC
    8/26/2025$83.00In-line → Outperform
    Evercore ISI
    More analyst ratings

    $HSIC
    $SAGE
    $SQNS
    $TIVC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Asher Daniel bought $62,974 worth of shares (12,300 units at $5.12) (SEC Form 4)

    4 - SEQUANS COMMUNICATIONS (0001383395) (Issuer)

    1/28/26 4:31:28 PM ET
    $SQNS
    Semiconductors
    Technology

    Large owner Asher Daniel bought $222,513 worth of shares (42,260 units at $5.27) (SEC Form 4)

    4 - SEQUANS COMMUNICATIONS (0001383395) (Issuer)

    1/22/26 5:09:00 PM ET
    $SQNS
    Semiconductors
    Technology

    Large owner Asher Daniel bought $225,174 worth of shares (39,831 units at $5.65) (SEC Form 4)

    4 - SEQUANS COMMUNICATIONS (0001383395) (Issuer)

    1/20/26 5:41:51 PM ET
    $SQNS
    Semiconductors
    Technology

    $HSIC
    $SAGE
    $SQNS
    $TIVC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Vistagen Reports Fiscal Year 2026 Third Quarter Financial Results and Provides Corporate Update

    PALISADE-4 Phase 3 Trial of fasedienol for acute treatment of Social Anxiety Disorder proceeding, with topline results from the randomized portion of the trial expected in the first half of 2026 Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today reported financial results for its fiscal year 2026 third quarter ended December 31, 2025, and provided a corporate update. "We have reviewed available data from PALISADE-3 and implemented moderate refinements, including retraining, site rationalization, and operational en

    2/12/26 4:30:00 PM ET
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sequans Communications Unaudited Fourth Quarter and Full Year 2025 Financial Results

    Paris, France--(Newsfile Corp. - February 10, 2026) - Sequans Communications S.A. (NYSE:SQNS) ("Sequans" or the "Company"), a leading provider of 5G/4G cellular IoT semiconductor solutions and a pioneer in Bitcoin treasury, today announced unaudited financial results for the fourth quarter and full year ended December 31, 2025.Fourth Quarter and Full Year 2025 Summary Unaudited Results Table (*):(in US$ millions, except share and per share data)Q4 2025Q3 2025 (1)Q4 2024Full year 2025Full year 2024Revenue $7.0 $4.0 $11.0 $27.2 $36.8 Gross profit $2.6 $1.7 $7.4 $14.8 $27.7 Gross margin (%) 37.7 % 42.4 % 67.4 % 54.3 % 75.3 %Operating income (loss) ($74.5) ($20.5) ($5.6) ($110.3) $69

    2/10/26 6:00:00 AM ET
    $SQNS
    Semiconductors
    Technology

    Vistagen to Report Fiscal Year 2026 Third Quarter Results and Host Corporate Update Conference Call on February 12, 2026

    Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced it will host a conference call and webcast on Thursday, February 12, 2026, at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to report results for its fiscal year 2026 third quarter ended December 31, 2025, and provide a corporate update. The conference call is being webcast live, and a link can be found under "Events" in the Investors section of the Company's website. Please click on the webcast link and follow the prompts for registration and access at

    2/4/26 8:30:00 AM ET
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HSIC
    $SAGE
    $SQNS
    $TIVC
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    August 4, 2023 - La FDA aprueba el primer tratamiento oral para la depresión posparto

    For Immediate Release: August 04, 2023 El día de hoy, la Administración de Alimentos y Medicamentos de los Estados Unidos (FDA, por sus siglas en inglés) aprobó Zurzuvae (zuranolona), el primer medicamento oral indicado para tratar la depresión posparto (DPP) en mujeres adultas. La DPP es un episodio depresivo grave que generalmente ocurre después del parto, pero también puede comenzar durante las últimas etapas

    8/8/23 9:34:19 AM ET
    $SAGE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    August 4, 2023 - FDA Approves First Oral Treatment for Postpartum Depression

    For Immediate Release: August 04, 2023 Today, the U.S. Food and Drug Administration approved Zurzuvae (zuranolone), the first oral medication indicated to treat postpartum depression (PPD) in adults. PPD is a major depressive episode that typically occurs after childbirth but can also begin during the later stages of pregnancy. Until now, treatment for PPD was only available as an IV injection given by a health

    8/4/23 6:50:31 PM ET
    $SAGE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HSIC
    $SAGE
    $SQNS
    $TIVC
    SEC Filings

    View All

    SEC Form 10-Q filed by Vistagen Therapeutics Inc.

    10-Q - Vistagen Therapeutics, Inc. (0001411685) (Filer)

    2/12/26 4:38:00 PM ET
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vistagen Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Vistagen Therapeutics, Inc. (0001411685) (Filer)

    2/12/26 4:35:48 PM ET
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Sequans Communications S.A.

    6-K - SEQUANS COMMUNICATIONS (0001383395) (Filer)

    2/10/26 6:00:41 AM ET
    $SQNS
    Semiconductors
    Technology

    $HSIC
    $SAGE
    $SQNS
    $TIVC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    VistaGen downgraded by Jefferies with a new price target

    Jefferies downgraded VistaGen from Buy to Hold and set a new price target of $0.90

    12/17/25 2:23:33 PM ET
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    VistaGen downgraded by Maxim Group

    Maxim Group downgraded VistaGen from Buy to Hold

    12/17/25 12:23:57 PM ET
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    VistaGen downgraded by William Blair

    William Blair downgraded VistaGen from Outperform to Mkt Perform

    12/17/25 11:34:15 AM ET
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HSIC
    $SAGE
    $SQNS
    $TIVC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Asher Daniel bought $62,974 worth of shares (12,300 units at $5.12) (SEC Form 4)

    4 - SEQUANS COMMUNICATIONS (0001383395) (Issuer)

    1/28/26 4:31:28 PM ET
    $SQNS
    Semiconductors
    Technology

    Large owner Asher Daniel bought $222,513 worth of shares (42,260 units at $5.27) (SEC Form 4)

    4 - SEQUANS COMMUNICATIONS (0001383395) (Issuer)

    1/22/26 5:09:00 PM ET
    $SQNS
    Semiconductors
    Technology

    Large owner Asher Daniel bought $225,174 worth of shares (39,831 units at $5.65) (SEC Form 4)

    4 - SEQUANS COMMUNICATIONS (0001383395) (Issuer)

    1/20/26 5:41:51 PM ET
    $SQNS
    Semiconductors
    Technology

    $HSIC
    $SAGE
    $SQNS
    $TIVC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Sage Therapeutics Inc.

    SC 13G/A - Sage Therapeutics, Inc. (0001597553) (Subject)

    11/14/24 6:14:58 PM ET
    $SAGE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Vistagen Therapeutics Inc.

    SC 13G/A - Vistagen Therapeutics, Inc. (0001411685) (Subject)

    11/14/24 5:05:41 PM ET
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Vistagen Therapeutics Inc.

    SC 13G/A - Vistagen Therapeutics, Inc. (0001411685) (Subject)

    11/14/24 4:19:46 PM ET
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HSIC
    $SAGE
    $SQNS
    $TIVC
    Leadership Updates

    Live Leadership Updates

    View All

    Henry Schein Enters Exclusive Distribution Agreement for CytoChip's CLIA-Waived Hematology Analyzer

    Partnership Expands Access to FDA-Cleared CitoCBC® System Across the U.S. Henry Schein, Inc. (NASDAQ:HSIC) has entered into a new exclusive distribution agreement with CytoChip Inc. for its flagship product, the CitoCBC® system, a U.S. Food and Drug Administration (FDA) 510(k)-cleared device. Available now to Henry Schein customers in the United States, the CitoCBC system is the first cartridge-based Complete Blood Count (CBC) system to receive a CLIA Waiver, helping expand access to accurate, lab-quality testing at the point of care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260115495488/en/CLIA Waived CitoCBC System Des

    1/15/26 10:00:00 AM ET
    $HSIC
    Medical Specialities
    Health Care

    Henry Schein Names Frederick M. Lowery as Chief Executive Officer

    Industry veteran brings more than 20 years of healthcare distribution experience and operational excellence Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of healthcare solutions to office-based dental and medical professionals, today announced the appointment of Frederick M. Lowery as its new Chief Executive Officer ("CEO"), effective March 2, 2026, at which time he will join the Board of Directors. Mr. Lowery succeeds Stanley M. Bergman, who will step down as CEO after 35 years and continue to serve as Chairman of the Board to ensure a smooth and effective leadership transition. This press release features multimedia. View the full release here: https://www.businesswire

    1/12/26 7:00:00 AM ET
    $HSIC
    $TMO
    Medical Specialities
    Health Care
    Industrial Machinery/Components
    Industrials

    Vistagen Appoints Nick Tressler as Chief Financial Officer

    Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced the appointment of Nick Tressler as Chief Financial Officer (CFO), effective today, December 1, 2025. "I am excited to welcome Nick to Vistagen as our CFO. His financial and strategic acumen and extensive operational experience in the biopharmaceutical industry will be instrumental as we accelerate into our next phase," said President and Chief Executive Officer of Vistagen, Shawn Singh. "I look forward to his contributions to our leadership team and the po

    12/1/25 8:30:00 AM ET
    $AZN
    $SENS
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments

    $HSIC
    $SAGE
    $SQNS
    $TIVC
    Financials

    Live finance-specific insights

    View All

    Vistagen Reports Fiscal Year 2026 Third Quarter Financial Results and Provides Corporate Update

    PALISADE-4 Phase 3 Trial of fasedienol for acute treatment of Social Anxiety Disorder proceeding, with topline results from the randomized portion of the trial expected in the first half of 2026 Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today reported financial results for its fiscal year 2026 third quarter ended December 31, 2025, and provided a corporate update. "We have reviewed available data from PALISADE-3 and implemented moderate refinements, including retraining, site rationalization, and operational en

    2/12/26 4:30:00 PM ET
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sequans Communications Unaudited Fourth Quarter and Full Year 2025 Financial Results

    Paris, France--(Newsfile Corp. - February 10, 2026) - Sequans Communications S.A. (NYSE:SQNS) ("Sequans" or the "Company"), a leading provider of 5G/4G cellular IoT semiconductor solutions and a pioneer in Bitcoin treasury, today announced unaudited financial results for the fourth quarter and full year ended December 31, 2025.Fourth Quarter and Full Year 2025 Summary Unaudited Results Table (*):(in US$ millions, except share and per share data)Q4 2025Q3 2025 (1)Q4 2024Full year 2025Full year 2024Revenue $7.0 $4.0 $11.0 $27.2 $36.8 Gross profit $2.6 $1.7 $7.4 $14.8 $27.7 Gross margin (%) 37.7 % 42.4 % 67.4 % 54.3 % 75.3 %Operating income (loss) ($74.5) ($20.5) ($5.6) ($110.3) $69

    2/10/26 6:00:00 AM ET
    $SQNS
    Semiconductors
    Technology

    Vistagen to Report Fiscal Year 2026 Third Quarter Results and Host Corporate Update Conference Call on February 12, 2026

    Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced it will host a conference call and webcast on Thursday, February 12, 2026, at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to report results for its fiscal year 2026 third quarter ended December 31, 2025, and provide a corporate update. The conference call is being webcast live, and a link can be found under "Events" in the Investors section of the Company's website. Please click on the webcast link and follow the prompts for registration and access at

    2/4/26 8:30:00 AM ET
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care